Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer

• US 20070207181A1
• Filed: 03/03/2006
• Published: 09/06/2007
• Est. Priority Date: 03/03/2006
• Status: Active Grant

• Current Assignee: Advanced Cardiovascular Systems Incorporated
• Original Assignee: Advanced Cardiovascular Systems Incorporated
• Inventors: Kleiner, Lothar W., Kwok, Connie S.
• Granted Patent: US 7,713,637 B2
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C08B 37/0072 Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
• CPC Class Codes: C08G 65/331 containing oxygen cyclic ether compounds C08G65/26
• CPC Class Codes: C08L 2666/02 Organic macromolecular compounds, natural resins, waxes or and bituminous materials
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C08L 53/00 Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
• CPC Class Codes: C08L 71/02 Polyalkylene oxides
• CPC Class Codes: Y10T 428/3154 Of fluorinated addition polymer from unsaturated monomers
• CPC Class Codes: Y10T 428/31663 As siloxane, silicone or silane
• CPC Class Codes: Y10T 428/31786 Of polyester [e.g., alkyd, etc.]
• CPC Class Codes: Y10T 428/31935 Ester, halide or nitrile of addition polymer
• CPC Class Codes: Y10T 428/31971 Of carbohydrate

Abstract

Provided herein are a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.

Claims

1. A composition comprising a PEGylated hyaluronic acid (HA) and a PEGylated non-HA polymer,

wherein the PEGylated HA and the non-HA polymer are independently modified with poly(ethylene glycol) (PEG), PEG like molecule or a combination thereof, and

wherein the PEGylated HA has a molecular weight in the range from about 70,000 Daltons to 320,000 Daltons.

2. The composition of claim 1, wherein the PEG like molecule is selected from the group consisting of polyethers, polyglycols, polyalkylene oxides, and combinations thereof.

3. The composition of claim 1, wherein the PEGylated non-HA polymer is selected from the group consisting of polyesters, polyacrylates, PEGylated peptides, PEGylated proteins, and combinations thereof.

4. The composition of claim 1, wherein the PEGylated non-HA polymer is

5. The composition of claim 1, wherein the PEGylated non-HA polymer is PEGylated poly(lactic acid) (PLA).

6. The composition of claim 1, wherein the PEG molecule has a weight average molecular weight (M_w) below about 45,000 Daltons.

7. An implantable device comprising a coating that comprises the composition of claim 1.

8. An implantable device comprising a coating that comprises the composition of claim 2.

9. An implantable device comprising a coating that comprises the composition of claim 3.

10. An implantable device comprising a coating that comprises the composition of claim 4.

11. An implantable device comprising a coating that comprises the composition of claim 5.

12. An implantable device comprising a coating that comprises the composition of claim 6.

13. An implantable device comprising a coating that comprises the composition of claim 7.

14. The implantable device of claim 8, wherein the coating further comprises a bioactive agent.

15. The implantable device of claim 14, wherein the bioactive agent is selected, from the group consisting of paclitaxel;

docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O -[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), clobetasol, pimecrolimus, imatinib mesylate, midostaurin, prodrugs thereof, co-drugs thereof, and a combination thereof.

16. The implantable device of claim 15, which is a stent.

17. An absorbable stent formed of the composition of claim 1.

18. A method of treating, preventing or ameliorating a disorder in a patient comprising implanting in the patient the impantable device of claim 15,

wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.